Thyroid
Breast-INV | Breast-DCIS
Lung
Esophagus | Stomach | Colon | Pancreas
Endometrium | Cervix
Prostate | Kidney | Renal Pelvis and Ureter | Bladder | Testis
GIST | Skin


Prostate Biopsies

IHC table: TUO Mucinous Carcinomas
IHC table: Carcinomas of Unknown Origin
IHC table: Renal Carcinomas
IHC table: Germ Cell Tumors
Fields to view based on lens diameter
Molecular and IHC Tests
Download sorted Breast Prognostic Stage Groups table
Notification Contacts

Breast Carcinoma Worksheet 4.1.0.0

Specimen Data:
Procedure







Specimen Laterality



Specimen Integrity


Tumor/Specimen Location


Tumor Data:
Carcinoma Type:

NOTE: if no invasive tumor is identified post-therapy, you do not need to use this protocol

























Nipple involvement


Skin involvement







Peau d'orange (involving less than 1/3 of breast skin)
Inflammatory carcinoma present, clinically (at least 1/3 of skin)

Skeletal muscle involvement



Tumor Size (invasive component):

Angiolymphatic Invasion

Tumor Grading

Tubules


Nuclei


Mitoses


Overall grade:


In Situ Carcinoma:
Presence of in situ carcinoma




Architectural patterns






Nuclear grade







Margins:
MarginInvasive TumorIn Situ Tumor










MarginInvasive TumorIn Situ Tumor










MarginInvasive TumorIn Situ Tumor









Optional:



Staging
Lymph Node Status

SiteSampledPositive
(>2.0mm)
MicMets
(≤2.0mm,
>0.2mm)
ITCs
(≤0.2mm)
Sentinel lymph nodes
Axillary/intramammary nodes




Metastasis Status

Miscellaneous
Treatment Effect in Tumor






Treatment Effect in Lymph Nodes







Modifiers





Receptor Studies
ER-IHC
ER-IHC:
Result:
Strength:
Prior:
PR-IHC
PR-IHC:
Result:
Strength:
Prior:
Her2-IHC
Her2-IHC:
Result:
Prior:
Her2-FISH
Her2-FISH:
Result:
Prior:
Oncotype DX
Other Findings













Comments











Free-text Comments





Final Report